Series to feature leading experts discussing the current and future trends in the carotid treatment market TEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced a video series, “12 Days […]
Tag: InspireMD
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
– Generated 38.8% growth in CGuard™ revenue year-over-year – – Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 – – Announced strategic partnership with NAMSA, a med tech contract research organization (CRO), to accelerate […]
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company – — Management to Host Investor Conference […]
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
Credited with performing the first ever endovascular repair procedure in 1990 TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic […]
InspireMD Reports First Quarter 2022 Financial Results and Business Update
– 20% growth in CGuard™ revenue Year-over-Year – – C-Guardian FDA IDE Trial Completes First European Enrollment – – Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages – – European logistics hub established with BOMI Group –for direct market access as […]
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement Approval for CGuard from the French National Authority – – CGuard Included as Carotid Stent Treatment Option in National Institute […]
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application
– CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients – – CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and actively engaged at more than 140 study locations – TEL AVIV, Israel, Feb. […]
InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor
Dr. Siddiqui is recognized for his extensive experience in Microsurgical, Radiosurgical and Endovascular Techniques for the Comprehensive Management of Vascular Disease TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of […]
InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial
Live Case will be Broadcasted Today at 11:00am ET TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ […]
InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- – $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to […]
Recent
4C Medical Secures $175M Series D Preferred Stock Financing
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Popular
- No commented posts yet